Chiasma Inc

Chiasma — Investor Presentation (January 2021)

34 slides from Chiasma's investor presentation, Jan 6, 2021

  1. Slide 1: Chiasma Overview January 2021

    Chiasma Overview January 2021 | NASDAQ: CHMA Exhibit 99.2

  2. Slide 2: Forward-looking statements

    These slides and the accompanying presentation contain forward-looking statements and information. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expression

  3. Slide 3: Chiasma Overview

    Chiasma Overview MYCAPSSA® was FDA approved in June 2020 and launched in September 2020 as the first and only oral somatostatin analog (SSA) for patients with acromegaly Acromegaly patients on SSA injectables face significant treatment challenges Attractive U.S. commercial opportunity ~8,000 patient

  4. Slide 4: Acromegaly U.S. Market Overview

    z Acromegaly U.S. Market Overview Octreotide and lanreotide injections are broadly used as first-line pharmacological treatments ~90% of these patients are treated at fewer than 1,000 medical centers Potential addressable patient population of ~8,000 patients in the U.S.* Acromegaly is a rare diseas

  5. Slide 5: Injections Carry Significant Treatment Burdens

    experience pain during injection; half of these experienced continuing pain days later Injections Carry Significant Treatment Burdens1 Pain Suboptimal Symptom Control Lost Workdays Emotional Impact Injection Site Reactions Hardness (48%), nodules (38%), swelling (28%), bruising (16%) and inflammatio

  6. Slide 6: MYCAPSSA: First and only FDA-approved oral SSA for acromegaly

    MYCAPSSA® First and only FDA-approved oral SSA for acromegaly; developed using TPE

  7. Slide 7: Commercial Launch Strategy

    Commercial Launch Strategy Pituitary Centers Regional Referral Centers High Volume Community Endocrinologists Other Community Endocrinologists ~90% of patients receiving injectable SSA therapies are treated at fewer than 1,000 medical practices ~1,000 Target Accounts Acromegaly Market Overview Promo

  8. Slide 8: MYCAPSSA Phased Launch Approach

    MYCAPSSA Phased Launch Approach 2020 2021 SEP OCT NOV DEC JAN FEB MAR APR MAY JUN JUL AUG SEP OCT NOV DEC 10 Field Sales FTEs (Total 22 FTE Customer-Facing Team*) 22 Field Sales FTEs (Total 36 FTE Customer-Facing Team*) ~30 Field Sales FTEs Planned (Total ~45 FTE Customer-Facing Team*) Reduction of

  9. Slide 9: Expected Drivers for a Differentiated U.S. Launch

    SSA-treated acromegaly patients are readily identifiable and are managed by a small number of endocrinologists Priced competitively – significant advancement for payers, patients, and the healthcare system Octreotide is well known and has been used for ~30 years Strong and informed acromegaly patien

  10. Slide 10: Pricing Designed to Support Broad Payer Coverage

    Pricing Designed to Support Broad Payer Coverage MYCAPSSA: Compelling Value for Payers Wholesale Acquisition Cost (WAC) of $5,384 for 28-day supply at 40 mg starting dose (linear pricing for 60 mg and 80 mg) Oral option addressing a critical unmet need SSAs already reimbursed and in payers' budgets

  11. Slide 11: MYCAPSSA Adapts Well to Telemedicine

    Telehealth consultation with the clinician A prescription communicated over the phone or internet Mobile phlebotomy for labs Home delivery and oral administration MYCAPSSA Adapts Well to Telemedicine Reduces the need for office visits

  12. Slide 12: Comprehensive Multichannel Digital Campaign

    Comprehensive Multichannel Digital Campaign MYCAPSSA is the first and only FDA-approved oral somatostatin analog (SSA) for appropriate patients with acromegaly, providing effective and consistent biochemical control while freeing patients from the burden of injections. Activate Patients Paid Search

  13. Slide 13: Chiasma Access and Patient Support

    Chiasma Access and Patient Support Dedicated Patent Care Specialist Financial Assistance Benefits Investigation Specialty Pharmacy Interactions Coordination with Physician Offices Help patients with acromegaly get started on MYCAPSSA and support them throughout their treatment Chiasma case managers

  14. Slide 14: Top Tier Commercial and Medical Leaders in Place

    Top Tier Commercial and Medical Leaders in Place Scott McConnell | Head of Medical Affairs Built and led multiple Medical Affairs organizations at Kaleido Biosciences, Alkermes, and Cubist Pharmaceuticals / Merck & Co. Derek Brown | Head of Marketing Led the global team responsible for the commercia

  15. Slide 15: Our Science: TPE technology and MYCAPSSA clinical trials

    OUR SCIENCE TPE technology and MYCAPSSA clinical trials

  16. Slide 16: Validated TPE Delivery Technology Platform

    Capsules with TPE technology have an enteric coating to protect against degradation in the stomach. Once in the small intestine, the capsule is designed to dissolve and release the TPE formulation. TPE technology induces the reversible expansion of tight junctions between intestinal epithelial cells

  17. Slide 17: MYCAPSSA Phase 3 Trials for U.S. and Europe

    CHIASMA OPTIMAL Phase 3 trial, met primary and all secondary endpoints completed in 2019 MYCAPSSA® Phase 3 Trials for U.S. and Europe MPOWERED Phase 3 trial top-line data show Non-inferiority to leading SSA injectables Basis for U.S. approval Rigorous placebo-controlled trial Designed to support EMA

  18. Slide 18: CHIASMA OPTIMAL Phase 3 Study Design

    CHIASMA OPTIMAL Phase 3 Multinational, Randomized, Placebo-Controlled Study Double-blind placebo-controlled (DPC) (36 Weeks) Open Label Extension Primary Endpoint Proportion of patients who maintain biochemical response (average of week 34 and 36 IGF ≤ 1.0 x ULN ) Pre-defined Withdrawal Criteria (Bo

  19. Slide 19: Primary & All Secondary Endpoints Met

    Endpoints Octreotide (N=28) Placebo (N=28) P-value MAINTENANCE of CONTROL Mean IGF-1 at end of oral treatment 0.97 x ULN 1.69 x ULN PRIMARY Proportion maintaining IGF-1 response 58% 19% 0.008 SECONDARY Proportion maintaining GH response 78% 30% 0.001 Time to IGF-1 > 1.0 x ULN Time to IGF-1 ≥ 1.3 x U

  20. Slide 20: MYCAPSSA Demonstrated as Safe & Well-Tolerated

    Octreotide capsules Placebo Subjects with: n % n % At least one TEAE 28 100.0 27 96.4 Treatment-related TEAE 18 64.3 15 53.6 SAEs 2 7.1 1 3.6 Treatment-related SAEs 0 0.0 0 0.0 Severe TEAEs 3 10.7 7 25.0 TEAE leading to study drug discontinuation 2 7.1 1 3.6 TEAEs of special interest (acromegaly sym

  21. Slide 21: CHIASMA OPTIMAL 48-Week Open Label Extension Data

    The mean of the IGF-1 levels for the population of all MYCAPSSA treated patients that completed the 36-week, double-blind placebo controlled (DPC) CHIASMA OPTIMAL trial and continued into the OLE (n=19) were maintained within normal limits at the end of the 48-week OLE period. 90% of patients enroll

  22. Slide 22: MPOWERED Non-inferiority Study Design and Top-line Data

    MPOWERED Non-inferiority Study Design and Top-line Data Last Injection Day (-28) Screening First Dose 6-Month Run-in Phase Responders Randomized to 9-Month Controlled Phase (RCT) Open Label Extension Follow for safety and efficacy 60% (55 pts) 40% (37 pts) Non-Responder Sub-study or Non-Responders S

  23. Slide 23: Higher Baseline IGF-1 Levels in the MYCAPSSA Arm

    Higher Baseline IGF-1 Levels in the MYCAPSSA Arm Compared to Injectable SSA Arm MYCAPSSA Injectable Long-acting SSAs Total (N=55) Total (N=37) Week 26 IGF-1 (categorical) (n [%]) ≤ 1 x ULN 37 (67%) 29 (78%) > 1 to < 1.3 x ULN 12 (22%) 8 (22%) ≥ 1.3 x ULN 6 (11%) 0 (0%) Week 26 IGF-1 (ULN) Mean (SD)

  24. Slide 24: MYCAPSSA Non-inferior to Long-acting Injectable SSAs

    MYCAPSSA Non-inferior to Long-acting Injectable SSAs Achieved the pre-specified non-inferiority margin of -20% Primary Endpoint: IGF-1 Time Weighted Average (TWA)1 throughout the RCT phase < 1.3 x ULN 1 TWA response represents an integrated measure of efficacy across time. It is derived as the area

  25. Slide 25: Mean IGF-1 Levels Were Maintained Within Normal Limits

    Mean IGF-1 Levels Were Maintained Within Normal Limits Baseline of RCT Baseline of RCT End of Treatment End of Treatment

  26. Slide 26: MYCAPSSA Appeared to be Safe and Well-Tolerated

    MYCAPSSA Appeared to be Safe and Well-Tolerated MYCAPSSA Injectable Long-acting SSAs Subjects with: n % n % At least one TEAE 39 70.9 26 70.3 Treatment-Related TEAE 19 34.5 15 40.5 SAEs 3 5.5 3 8.1 Severe TEAEs 5 9.1 4 10.8 TEAE Leading to Study Drug Discontinuation(1) 1 1.8 0 0 SAEs - Serious Adver

  27. Slide 27: Incidence of Most Common TEAEs

    MYCAPSSA Injectable Long Acting SSAs Total (N=55) Total (N=37) Gastrointestinal disorders Flatulence 14 (25.5) 8 (21.6) Nausea 11 (20.0) 3 (8.1) Diarrhea 6 (10.9) 5 (13.5) Abdominal pain 5 (9.1) 3 (8.1) Constipation 3 (5.5) 5 (13.5) Infections & infestations 5 (9.1) 0 Nasopharyngitis General disorde

  28. Slide 28: MYCAPSSA Patents Timeline

    MYCAPSSA® Patents Timeline Strong U.S. and EU Patent Position June 2020 U.S. Marketing Approval June 2027 Expiration of U.S. Orphan Exclusivity, assuming granted by FDA September 2029 Expiration of Formulation Patent (U.S. & EU) February 2036 Expiration of U.S. Issued Dosing Patent (EU patent approv

  29. Slide 29: Key 2020 Milestones Achieved

    Timing (Est.) Anticipated Key Milestones Status Q1:2020 MYCAPSSA Octreotide Capsule NDA Acceptance from the FDA Mid-2020 MYCAPSSA CHIASMA OPTIMAL Phase 3 Study Data Presentation Mid-2020 MYCAPSSA PDUFA Approval (June 2020) Mid-2020 Publish CHIASMA OPTIMAL Phase 3 Study Data in Peer Reviewed Journal

  30. Slide 30: Planned 2021 Milestones

    Timing (Est.) Anticipated Key Milestones 2021 Execute successful MYCAPSSA U.S. Launch Mid-2021 Publish MPOWERED Phase 3 Study Data in Peer Reviewed Journal Mid-2021 Planned MYCAPSSA EMA Regulatory Submission 2021 MYCAPSSA MPOWERED Virtual Data Presentation at Medical Conferences Planned 2021 Milesto

  31. Slide 31: Financial Summary

    Financial Summary* * Unaudited cash, cash equivalents and marketable securities of ~$135 million at December 31, 2020. (In thousands, except per share data) Qtr. Ended Sept. 30, 2019 Qtr. Ended Sept. 30, 2020 Product Revenues, net $ - $142 Gross Profit $ - $139 Selling, General & Administrative $4,1

  32. Slide 32: Management Team and Board of Directors

    Raj Kannan Chief Executive Officer Management Team Mark J. Fitzpatrick President (Principal Financial Officer) William Ludlam, M.D., Ph.D. Clinical Development & Medical Affairs Anand Varadan Chief Commercial Officer Drew Enamait Finance & Administration Lee Giguere General Counsel Shoshie Katz VP,

  33. Slide 33: Successful Launch with MYCAPSSA Enables a Bright Future

    Successful Launch with MYCAPSSA Enables a Bright Future Clinical Stage Company Commercial Stage Company with Validated TPE Platform Vision: Become a Successful Commercial Company with a Promising Pipeline

  34. Slide 34: Thank You

    Thank You January 2021 | NASDAQ: CHMA

Chiasma — Investor Presentation (January 2021) on 6ix